复发缓解型多发性硬化症的治疗用生物制剂临床研究进展

Clinical research progress of biological agents of relapsing remitting multiple sclerosis

多发性硬化症(multiple sclerosis)是一种中枢神经系统自身免疫性疾病,属于慢性炎症性脱髓鞘性疾病,在我国属罕见病。目前临床用于治疗复发缓解型多发性硬化症的一线用药主要有干扰素β(interferonβ)、聚乙二醇干扰素-β1a(pegylated interferon-β1a)、醋酸格拉替雷(glatiramer acetate)、特立氟胺(teriflunomide)及富马酸二甲酯(dimethyl fumarate)。本文对近年来用于治疗复发缓解型多发性硬化症的治疗用生物制剂临床研究进展作一简要概述。

Multiple sclerosis is a central nervous system autoimmune disease,which belongs to chronic inflammatory demyelinating diseases and is rare in China.At present,the first-line drugs for the treatment of relapsing-remitting multiple sclerosis mainly include interferon-β,pegylated interferon-β1a,glatiramer acetate,teriflunomide and dimethyl fumarate.This airtcle provided a brief overview of the clinical research progress on therapeutic biological agents of relapsing-remitting multiple sclerosis in recent years.